Stock Taper
SCREENER COMPARE ANY 2 STOCKS
AUPH
AURINIA PHARMACEUTICALS INC.
NASDAQ
$16.29
▼ DOWN 1.12% (-0.18)

KEY STATISTICS

Market Cap$2.09 B
52w High$19.25
52w Low$10.34
Dividend Yield—
Frequency—
P/E15.97
Volume630.57K
Shares Out.128.60M

COMPANY

LEADERSHIP

Kevin C. Tang
CHIEF EXECUTIVE
Kevin C. Tang

COMPENSATION 2026

Salary$822,877
Stock Awards$1,965,321
Incentive Plan Pay$864,021
All Other Comp.$13,182
Total$5,858,590

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 3, 2014
METHOD OF GOING PUBLIC
Dual Listing
FULL TIME EMPLOYEES
128

PRICE TARGET

Target High$16.00
Target Low$16.00
Target Median$16.00
Target Consensus$16.00

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$83.61M
NOV
3
TUE

SPLIT RECORD

DATETYPERATIO
2013-11-08Reverse1:50
2013-10-23Reverse1:50

PRICE

$16.29 ▼ DOWN 1.12% (−$0.18)
OVERLAYS
$16.27$16.35$16.429:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM16.29

About Aurinia Pharmaceuticals Inc.

https://www.auriniapharma.com ↗

Aurinia Pharmaceuticals Inc. is a Canadian biopharmaceutical company developing and commercializing therapies like LUPKYNIS for unmet medical needs such as lupus nephritis, with collaborations including Otsuka Pharmaceutical.

INDUSTRY

Biotechnology

A PRODUCT AURINIA PHARMACEUTICALS INC. IS KNOWN FOR

LUPKYNIS (voclosporin)
LUPKYNIS (voclosporin)

LUPKYNIS (voclosporin) is the first FDA-approved oral treatment for active lupus nephritis, serving as Aurinia's main product and revenue source.

COMPETITORS

COMPETITOR
AZN COMPARE
CABA COMPARE
GSK COMPARE
NVS COMPARE
VERA COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$70.63M $74.17M ▲$73.56M ▼$79.41M ▲
License Collaboration and Royalty Revenue$2.84M $2.94M ▲$4.14M ▲$3.81M ▼

Revenue by Geography

MapREGIONFY2022FY2023FY2024FY2025
UNITED STATES$102.46M $157.96M ▲$210.09M ▲$263.84M ▲
JAPAN$31.48M $17.55M ▼$25.04M ▲$19.21M ▼
Other Country$89K $0 ▼— —

ETFS HOLDING THIS STOCK

ETFS HOLDING
115
LISTED HERE
23
RANKED BY POSITION SIZE
IWM
0.06% · 3.0M
VTWO
0.06% · 669.2K
FESM
0.11% · 439.0K
PSC
0.14% · 234.4K
R2SC.L
0.06% · 226.6K
AVSC
0.09% · 180.8K
XRS2.F
0.06% · 109.3K
BBP
1.28% · 92.6K
JPSE
0.24% · 85.6K
FSML
0.74% · 68.1K
OMFS
0.34% · 58.6K
RSSL
0.06% · 56.9K
GSSC
0.08% · 54.8K
EES
0.10% · 41.7K
AFSM
0.29% · 23.0K
ROSC
0.47% · 15.4K
TILT
0.01% · 8.1K
URTY
0.02% · 4.8K
IVSS
0.12% · 2.1K
SXQG
0.04% · 1.5K
USFMDN.MX
0.00% · 687
AESG
0.32% · 396
RESM
0.06% · 221

INSTITUTIONAL OWNERSHIP

SHARES OWNED
45.00%
HOLDERS
374
TOP 12 OF 374 · RANKED BY POSITION SIZE
Tang Capital Management LLC
13.0M sh · $221.36M
Blackrock Inc.
9.3M sh · $52.94M
Blackrock, Inc.
8.2M sh · $139.04M
Goldman Sachs Group Inc
5.6M sh · $95.36M
Nea Management Company, LLC
4.0M sh · $67.37M
Two Sigma Investments, LP
3.5M sh · $58.84M
Arrowstreet Capital, Limited Partnership
3.4M sh · $54.03M
State Street Corp
2.7M sh · $29.77M
Morgan Stanley
2.3M sh · $39.17M
Pictet Asset Management Ltd
2.2M sh · $28.13M
Marshall Wace, Llp
2.0M sh · $34.69M
Geode Capital Management, LLC
1.7M sh · $28.86M

RATINGS SNAPSHOT

Overall rating: A-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity5
Return On Assets5
Debt To Equity3
Price To Earnings3
Price To Book2
Overall Score4

INSIDER TRADES

★
OFFICER: CHIEF LEGAL OFFICER
Robertson Stephen P.
Sale · 21.0K shares
2026-08-21
★
DIRECTOR
Nova Tina Susan
Purchase · 23.9K shares
2026-06-04
★
DIRECTOR
Bailey Jeffrey Allen
Purchase · 23.9K shares
2026-06-04
★
DIRECTOR
Johnson Craig A
Purchase · 23.9K shares
2026-06-04

MOST RECENT ANALYST GRADES

GRADE SUMMARY
SECTOR PERFORM 2
MARKET PERFORM 1
BUY 1
4 GRADES IN THE LAST 12 MONTHS
RBC Capital SECTOR PERFORM Leerink Partners MARKET PERFORM Jefferies BUY RBC Capital Mkts SECTOR PERFORM

SECTORS PEERS

PEERPRICE
ABCL$11.35COMPARE
CLDX$39.12COMPARE
VERA$34.19COMPARE
BHVN$15.41COMPARE
NUVB$6.66COMPARE
HRMY$39.21COMPARE
STOK$31.62COMPARE
IMCR$36.62COMPARE